Skip to main content
Fig. 5 | Biomaterials Research

Fig. 5

From: Verapamil-loaded supramolecular hydrogel patch attenuates metabolic dysfunction-associated fatty liver disease via restoration of autophagic clearance of aggregated proteins and inhibition of NLRP3

Fig. 5

In vivo imaging and biodistribution of Vera-FITC@CLCMP patch in mice. A Photographs of verapamil and verapamil-FITC conjugate solutions under daylight and UV light for 365 nm excitation wavelength. B Vera-FITC@pullulan or Vera-FITC@CLCMP patches were applied to the dorsal skin of hairless mice. C Fluorescence imaging of mice at 1–4 days after treatment with CLCMP, Vera-FITC@pullulan, or Vera-FITC@CLCMP patches. D Fluorescence intensity was quantified. E Fluorescence imaging of histological sections of the dorsal skin of mice treated with Vera-FITC@CLCMP patch at indicated time points. Nuclei were stained with DAPI (blue). Scale bar, 100 μm. A line scan across the marked line is shown in (F). G Ex vivo fluorescence imaging of heart, liver, spleen, lung, kidney, and pancreas at 1 day and 4 days after treatment with CLCMP, Vera-FITC, Vera@pullulan, or Vera-FITC@CLCMP patches. H Fluorescence intensity of each organ was quantified. Data is shown as mean ± SEM. ***p < 0.001 (One-way ANOVA, followed by Tukey’s test)

Back to article page

Biomaterials Research

ISSN: 2055-7124

Contact us